Longeveron Inc., a clinical stage biotechnology company developing cellular therapies for chronic age-related and life-threatening conditions, has selected Biorasi LLC as its clinical research organization (CRO) to help conduct its Phase 2 clinical trial evaluating Lomecel-B infusion in Alzheimer’s Disease (AD) subjects.      Biorasi has extensive experience in the management and execution of neurology clinical studies, and in phase I through IV trials in the U.S. and globally.   “Partnering...